BACKGROUND: N ausea and vomiting are frequ ent adverse effects of patientcont rolled epidural analgesia (PCEA) with opioids.
INTRODUCTION
Patient-controlled epidural analgesia (PCEA) has been used to reduce postoperative pain after majot abdominal surgery. I A combination of local anesthetic with opioid has been commonly used to improve the quality of pain relief in PCEA, but this treatment increases postoperative nausea and vomiting (PONV) during pCEA.2 PONY may result in electrolyte abnormalities and dehydration.t Persistent retching or vomiting following surgery can put tension on suture lines, result in hematomas beneath surgical flaps, and place the patient at risk for pulmonary aspiration of vomit. Therefore, these have led to attempts to combine opioid and drugs such as droperidolt-' and naloxone'' in PCEA solution in the hope of minimizing the adverse effects (AEs) of opioids. However, continuous infusion of droperidol did not decrease PONV5 and naloxone, an opioid antagonist, did not increase analgesia.f A short-acting water-soluble benzodiazepine, midazolam has been reported to decrease the incidence and severity of PONV. 7-11 Midazolam has also been found to be effective in the treatment of established PONV. 12 Midazolarn administered intrathecal-ly12-14 or epidurally'<l? has been reported to have an analgesic effect. A prospective, randomized, double-blind trial by Nishiyama et al 16 found that adding midazolam (10-20 mg for 12 hours) to continuous epidural infusion of bupivacaine (100 mg) for postoperative pain provided better analgesia than bupivacaine alone without a deep sedative effect in 80 patients (mean age, 58 years; weight, 56.5 kg). In addition, Nishiyama et al 17 conducted a second prospective, randomized study that investigated the effects of adding midazolam to the postoperative epidural analgesia with 2 different doses (180 vs 90 mg) ofbupivacaine in 100 postgastrectomy patients (age, 40-75 years). It was reported that epidural-infused midazolam (10-20 mg for 12 hours) with bupivacaine 180 mg provided better analgesia compared with bupivacaine alone. In a prospective, randomized, double-blind trial of 60 patients (mean age, 26.1 years; weight, 54.5 kg) who underwent spinal anesthesia for cesarean delivery, intrathecal midazolam 1 mg (5 %) and 2 mg (5 %) added to bupivacaine appeared to reduce PONY compared with controls (85%) during cesarean delivery.P However, based on a search of the literature on MEDLINE (search terms: epidural analgesia, midazolam, opioid, and postoperative nausea and vomiting; years, 1990-2009), no published data were available for the antiemetic effect of midazolam added to opioid-local anesthetics-based PCEA. Therefore, we hypothesized that epidural midazolam may reduce PONY during PCEA and reduce the overall infused volume of PCEA.
The present study assessed the effect of midazolam added to fentanyl-ropivacaine PCEA on the incidence of PONY in patients having subtotal gastrectomy. In addition, we investigated total consumed volume of PCEA, pain intensity, sedation level, respiratory complications, and other AEs.
PATIENTS AND METHODS
T his prospective, rand om ized , double-blind, cont rolled stu dy was approved by th e et hics com m ittee of Kyun gpook N ational Uni versit y H ospit al, Daegu, Republic of Korea. We included consecutive American Societ y of Anesthesiologi sts Ph ysical Status Classification I (no organic, ph ysiologi c, biochemical, or psychiatric di sturbance) and II (mi ld to moderat e syste m ic d isturbance th at mayor may not be relat ed to th e reason for surgery) smo ki ng pat ients with gas tric cancer, undergo ing elective su bto tal gas trectomy. W ritten informed consent was obtai ned from all patients. Pat ient s wit h a history of d rug ab use, allergi es co any of the drugs, prev ious PONY or mot ion sicknes s, who had com plained of nausea or vom iting or received any antiem etic medication with in 24 hours before surgery, or wh o had liver or renal dysfunction were excluded.
The night before surgery, all patients were instructed on how to use the PCEA device. No premedication was ad m inistered . The anesthetic regimen and postoperative pain management were sta ndardized in all patients. In th e operating room, patients were placed in th e siccing position and an ep id ural catheter was inserted via 18-gauge Tuoh y needle at the T8/T 9 interspace and was ad vanced 3 co 4 cm int o th e epid ura l space in a cephalad d irect ion . A standa rd test dose of lidocaine 2% with epi nephrine 5 pg/mL was injected to rule out intrathecal or intravas cular position of th e cathe ter. Sensory block (loss of pinprick test) covering th e area of the proposed incision was induce d by inject ing 8 to 12 mL of 0.375% ropivacaine. General anesth esia was induced with propofol (2 mg/kg) and rocur onium (l .0 mg/k g) and m aintained with 66 % nitrous oxide in oxygen with a sma ll concentrat ion (0. 5%-0.9%) of isoflurane, Within 30 minutes of induction , a continuous epidural infusion of 0 .375% ropi vacaine at 0.1 mL/kg /h was initiated . Lungs were mechanically vent ilated maintain ing an end tidal carbon dioxid e concent ration of 4. 6 kPa. It is standard pract ice to ad mi nis ter opioids during th is surg ery. Ho wever, intraoperative op ioids increase PONY incidence"; th erefore, opioids were not admini ste red d uri ng the present surge ry. 3 An infusi on of Ringer's solurio n (l 0 mL/k g/h) was admi nistered intravenously toge ther with 4-mg boluses of ephedrine co m aintain mean arterial pressure within 20% of baseline values throu ghout surgery. At the end of surgery, glycopyrrolate 7 pg/kg and pyridostigmine 30 Ilg /kg were administered intravenously for antagonism of residual neuromuscular blockade and the epidural infusion of 0 .375% of ropivacaine was stopped .
In the postanesthetic care unit , postoperative pain relief was provided by using PCEA with a standard pump (Abbott Ambulatory Infusion Manager plus, Abbott Laboratories , North Ch icago, Ill ino is). Patients were rando m ly assig ned to receive 0 .2 % rop ivacaine mixed with fenta nyl 4 pg/rnl. and midazolam 0.2 mg /mL (test g roup) or 0.2% ropivacaine mix ed with fent an yl 4 pg/rnl, (cont rol g roup). In the present study, m idazolam was epid urally adm inist ered at a mean rate of 0.98 mg/hr. One anesthesiolog ist, not involved in th e study, generated the randomization sequence. Assignment was double bl ind ed with respect to treatment. Sealed , sequenced envelopes for assignment were opened on arrival in the preoperating room. Another anesth esiolog ist , not involved in th e stu dy, prepared the stu dy medicat ions. These study drugs were concealed in numbered opaque envelopes, and all study personnel and participants were blinded to treatment assignment for the duration of the study. The PCEA infusion was set to deliver 4 mLlhr of the study solution, with a bolus of 2 mL per demand and a IS-minute lockout time. Based on previous reports,16.l7 midazolam 0.2 mg/mL was chosen. Therefore, the patients in this study could receive midazolam at a rate of 0.8 to 1.6 mg/hr.
The primary end point was the incidence of PONV and secondary end points were total consumed volume of PCEA, pain intensity, sedation level, respiratory complication, and any other AEs during PCEA. The epidural catheter was removed at 72 hours after surgery and then total infused volume of PCEA solution for 72 hours after surgery was measured. Assessment of PONV, sedation level, pain intensity, usage of rescue antiemetic and analgesic, and any noted AEs were collected at 2, 6, 12,24,48, and 72 hours after the end of surgery by direct questioning by a study-blinded trainee anes thesiologist.
Nausea was defined as a subjectively unpleasant sensation associated with awareness of the urge to vomit, while vomiting was defined as the forceful expulsion of gastric contents from the mouth. For the purpose of data collection, retching (defined as the same as vomiting but without expulsion of gastric contents) was considered vomiting. A rescue antiemetic, ondansetron 4 mg IV, was administered if vomiting occurred, or at the patient's request to treat intolerable nausea.
Sedation levels were assessed using a 4-point scale (0 = awake; 1 = mildly sedated, easy to wake up when spoken to; 2 = moderately sedated, easy to wake up when slightly shaken; and 3 = deeply sedated, difficult to wake up when shaken).18 Pain intensity scores were measured with a visual analog scale (VAS) from a (no pain) to 10 (the worst possible pain). If analgesia was inadequate (verbal rate score on coughing >4) and patients ask for more analgesia, ketorolac 50 mg IV was administered as a rescue analgesic.
Using pulse oximetry, oxygen saturation was continuously measured during PCEA. Reduction in oxygen saturation to <92% was treated with supplemental oxygen via face mask, and need for oxygen treatment during the postoperative period was recorded as a minor respiratory complication. However, a patient with hypoxemia refractory to oxygen was regarded as unacceptable in this context and the patient was excluded. In addition, any AEs that occurred during the study were recorded.
STATISTICAL ANALYSIS
A power analysis with a pilot study revealed that a group size of 29 would be required to detect a reduction in the incidence ofPONV from 55% to 20% (P = 0.05; power = 0.8). Statistical analysis was performed using SPSS version 12.0 (SPSS Inc., Chicago, Illinois). The t test was used to compare continuous variables; when data were not normally distributed, the Mann-Whitney U test was used. ANOVA for repeated measures was used to analyze over time. Categorical data were analyzed using the contingency table analysis with the Fisher exact test and the X 2 test. Categorical variables are presented as number (%), while continuous variables are presented as mean (SO).
RESULTS
Sixty consecutive patients were enrolled. No patients were excluded by exclusion criteria and all enrolled patients completed this study. There were no significant between-group differences in regard to demographic data or duration of anesthesia (Table I) . Table II shows the incidence of PONV and patients requiring rescue antiernetics. The incidence of nausea was significantly less in the test group than that in the control group (2 (7%} vs 10 f33%}; P = 0.02). The overall frequency of PONV in the test group was significantly less than that in the control group (2 (7%} vs 12 (40%}; P = 0.006). Numerically more patients in the control group received rescue antiemetic medication, but there was no statistically significant difference (4 (l3%} vs 0). Table III shows sedation scores, respiratory complications, pruritus, mean consumed PCEA volume, and rescue analgesic. There was no difference in the level of sedation between the 2 groups. No patients developed deep sedation or hypoxemia requiring oxygen therapy. In addition, no patients were excluded due to severe hypoxemia refractory to oxygen. With respect to pruritus, there was no significant betweengroup difference. The mean (SD) infused volume of PCEA in the test group was significantly lower (351.2 (49 .8} ml vs 392.3 (68.9} ml.; P = 0.01). However, there were no significant differences in the usage of rescue analgesics (2 (7 %} vs 5 (17 %}) or VAS pain score on cough during the observation period ( Figure) .
No patient reported moderate or severe sedation, respiratory depression, or hypoxemia. In addition, there were no severe AEs observed during this study.
Pruritus observed in this study was relatively mild, and there were no severe AEs in the 2 groups. 
DISCUSSION
The overall incidence of PONY in patients receiving midazolam-fentanyl-rop ivacaine PCEA was significantl y reduced compared with fentanyl-ropivaca ine PCEA wit hou t increasing the occur rence of AEs in these patient s who underwent partial gastrectomy. In add ition, the total infused volume in the test group was significantly less compared with th at in the control gr oup. PONY is one of th e most distressing complications after anesthesia and surgery.f In the pr esem study, patients' specific surgical and anesthetic factors that mighr modify the incidence of PONY were balanced between g roups. Opioids inc rease PONY via st im ulating the chemorecepto r zone in the area postrerna of th e medulla.19 T herefore, the differen ces in the incidence of PON Y can be attributed to the study drug . In the present study, th e incidence of PON Y in th e cont rol gro up was 40%. In Table III . Sedation, hypoxemia, pruritus , infused volume of patient-controlled epidural analgesia (PCEA) solution, and consumption of rescue analgesics in smoking patients with gastric cancer undergoing elective subtotal gastrectomy (N = 60). T Sedati on level: 0 =awake; 1 =mildly sedated, easy to wake up when spoken to; 2 =moderately sedated , easy to wake up when slightly shaken; 3 = deeply sedated, diffic ult to wake up when shaken.
Ropivacaine-Ropivaca ine-
th e present study, th e inciden ce of PO N V in the tes t g roup was significantly less th an that in the control group. The antiemetic effect of m idazolam has been demonstrated with various obj ect s of study and various methods of ad rninisrration.Z"!' Di Flori o and Goucke" conducted a prospective, randomized , double-blind study in 20 patients (aged 18-82 years) with pe rsistent PONY refractory ro other conventional ant iemet ics comparing the ant iemeti c effect of midazolam bol us (1 rng) followed by infu sion of 1 mg/hr with placebo . It was reported that cumulative nausea score (26 vs 50; P = 0.04), vomi ting frequency (10% vs 70% ; P = 0 .02), and the use of rescue antieme tic (0% vs 70 %; P = 0 .003 ) were sig nificantly less in the midazolam group than those in placebo. San jay and Tauro" cond ucted a prospective, random ized, doub le-blind trial , comparing efficacy of midazolam versus ondanserro n, in 200 patie nts (mean age, 61 years; weight, 68 kg) on the incidence of PONY for 24 hours after cardiac surgery. A 6% incidence of PONY was observed in patients receiving midazolam in a dose of 0.02 mg/kg /hr after 1 mg bolus compared with a 21 % incidence rate in patients receiving ondansetron 0 .1 mg/kg IV every 6 hours (P < 0.001).
The exact mechanism by whi ch midazolam exerts its antiemetic act ion is not fully understood . Postu lated mec hanisms inclu de glycine mimetic inhibi tory effects.l ? enhancem ent of the inhibitory effects of y-am inobuty ric acid ,20 inhibition of dopa- suggested that intrathecal midazolam was involved in the release of an endogenous opioid, acting at spinal delta receptors. The prospective, randomized, double-blind trial by Tucker et aP3 found that midazolam 2 mg increased the analgesic effect of fentanyl 10 pg without AEs when the drugs were administered together intrathecally for labor pain (mean age, 29.7 years; weight, 68 kg). In the present study, there were no significant between-group differences in VAS pain score when coughing. However, total infused volume of PCEA in the test group was significantly less than that in the control group.
It has been found that intravenous continuous infusion of midazolam in a dose of about 1 mg/hr was effective for reducing PONV without sedative effects in patients who received opioids for postoperative pain conrrol.s-? The prospective, randomized, double-blind trial by U nlugenc er alII suggested that the antiemetic effect of rnidazolam lasted longer than the sedative effect in 453 patients (mean age, 44 years; weight, 66 kg). In the present study, there were no additional sedative effects in patients who received midazolam. However, a variety of midazolam doses should be investigated to determine its antiemetic effectiveness and tolerability profile.
Intrathecal midazolam provides segmental analgesia, but conflicting experimental studies have cast doubts on its safety. Malinovsky et al 25 reported necrosis, hemorrhage, and other histopathologic changes in 2 of 9 spinal cords of rabbits that had received a single intrathecal injection of midazolam 0.3 mg. However, various other experimental histopathologic studies have found that intrathecal midazolam does not cause any morphologic changes in the spinal cord. 26 , 27 Tucker et aP2 suggested that clinically useful doses of intrathecal midazolam 2 mg did not increase adverse neurologic symptoms compared with conventional treatments. Aguilar et a1 28 found that intrathecal infusion of midazolam for 13 months was tolerable for reducing chronic lower back pain in a patient with chordoma. Borg and Krijnerr'? reported cases of longterm (>2.5 years) administration of up to 6 mg/d of intrathecal midazolam in patients with refractory neurogen and musculoskeletal pain. It was found that midazolam did not cause any neurologic deficits. In the present study, rnidazolam was epidurally administered at a mean rate of 0.98 mg/hr, which was consistent with previous reporrs. 16 ,17 In addition, no patients who received epidural infusion of midazolam showed neurotoxic effects.
The findings should be considered within the context of the limitation of the study. The sample size of the study was relatively small. This study showed a lack of power to detect significant differences in secondary outcomes. In addition, all patients having a single type of surgery underwent a single type of general anesthesia. Therefore, the results may not be widely applicable to patients undergoing other procedures.
CONCLUSION
Midazolam added to fentanyl-ropivacaine PCEA was associated with a significant reduction in the incidence of PONY compared with fentanyl-ropivacaine alone, and a significant decrease in the amount of PCEA administered without a significant increase in AEs in these patients who underwent subtotal gastrectomy.
